Who is involved
The COVID-19 landscape has been marked by a series of variants since the pandemic began, with expectations that vaccines would effectively manage emerging strains. However, the recent emergence of the Cicada variant, designated BA.3.2, has disrupted this expectation. Initially detected in South Africa in November 2024, the Cicada variant has since spread to 23 countries, including the UK, raising alarms among health officials and the public alike.
As of March 30, 2026, the Cicada variant has been reported in the UK, where it is characterized by 70 to 75 genetic changes in its spike protein. This significant alteration raises concerns about the variant’s ability to evade the immunity provided by existing vaccines. The variant has been associated with symptoms such as a painful sore throat, fever, cough, fatigue, and nasal congestion, which are similar to those caused by other COVID-19 variants.
The decisive moment came when weekly detections of BA.3.2 surged, accounting for approximately 30% of COVID-19 sequences reported in Denmark, Germany, and the Netherlands from November 2025 to January 2026. This rapid increase in prevalence indicates that the Cicada variant may be spreading more efficiently than previous strains. Public health experts are closely monitoring the situation, as the variant’s mutations could lead to seasonal increases in COVID-19 activity.
Experts have voiced their concerns regarding the efficacy of current vaccines against the Cicada variant. Kyle B. Enfield, a prominent epidemiologist, stated, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” This statement underscores the urgency of evaluating vaccine strategies and the need for potential updates to immunization protocols to address this new threat.
Despite these concerns, there is currently no evidence that the Cicada variant causes more severe disease than previous variants. Enfield reassured the public, saying, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This information provides a glimmer of hope amidst the rising anxiety surrounding the variant.
The Cicada variant’s emergence reflects its namesake, an insect that lies dormant for years before reappearing. This characteristic mirrors the variant’s ability to remain undetected before spreading across borders. As of February 2026, the variant has been confirmed in 24 countries, raising the stakes for global health authorities.
Details remain unconfirmed regarding the long-term effectiveness of current vaccines against the Cicada variant, and the exact impact on public health remains unclear due to limited genomic detection and surveillance capacities in many countries. As the situation evolves, health officials are urging the public to remain vigilant and adhere to safety protocols to mitigate the spread of this new variant.
In summary, the emergence of the COVID 19 Cicada variant in the UK presents a new challenge in the ongoing battle against the pandemic. With its rapid spread and potential implications for vaccine efficacy, public health responses will be crucial in managing this evolving situation.